MATE 2 Inhibitors
- Name
- MATE 2 Inhibitors
- Accession Number
- DBCAT003953
- Description
Not Available
- Drugs
Drug Drug Description Copanlisib A PI3K inhibitor used to treat relapsed follicular lymphoma in adults. Abemaciclib A medication used to treat HR+ HER2- advanced or metastatic breast cancer. Brigatinib An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. Rucaparib A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat recurrent ovarian and prostate cancers in previously treated adults. Apalutamide An androgen receptor inhibitor used to treat non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer. Plazomicin An aminoglycoside antibiotic used to treat complicated urinary tract infections. Tafenoquine An antiparasitic agent used for the treatment and prevention of relapse of Vivax malaria. Levofloxacin A fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria of the upper respiratory tract, skin and skin structures, urinary tract, and prostate, as well as for post-exposure treatment of inhaled anthrax and the plague. Ciprofloxacin A second generation fluoroquinolone used to treat various susceptible bacterial infections. Cimetidine A histamine H2 receptor antagonist used to manage GERD, peptic ulcer disease, and indigestion. Baricitinib A Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. Pyrimethamine An antiparasitic drug used in the prevention and treatment of toxoplasmosis and malaria. Glasdegib A sonic hedgehog receptor inhibitor used to treat newly diagnosed acute myeloid leukemia in patients over 75 years who cannot receive intense chemotherapy. Pexidartinib An antitumor agent that is used for the treatment of rare disease tenosynovial giant cell tumors (TGCT) by inhibiting colony-stimulating factor 1 and its receptor. Fedratinib Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.[L8090,L47016] Istradefylline A selective adenoside A2A receptor antagonist indicated in adjunct to levodopa and carbidopa for the treatment of Parkinson's Disease. Lasmiditan An oral 5HT1F agonist used for the acute treatment of migraine headache with or without aura. Verapamil A non-dihydropyridine calcium channel blocker used in the treatment of angina, arrhythmia, and hypertension. Tazemetostat A methyltransferase inhibitor indicated to treat patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Trimethoprim An antifolate antibiotic often used in combination with sulfamethoxazole to treat a number of infections, including those of the urinary tract, respiratory tract, and gastrointestinal tract. Ranolazine An anti-anginal drug used for the treatment of chronic angina. Methylene blue An oxidation-reduction agent used for the treatment of pediatric and adult patients with acquired methemoglobinemia. Tucatinib A kinase inhibitor used to treat certain types of unresectable/metastatic HER-2 positive breast cancer. Capmatinib A kinase inhibitor targeting c-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer with MET exon 14 skipping. Risdiplam An oral mRNA splicing modifier used in the treatment of spinal muscular atrophy (SMA). Pralsetinib A RET receptor tyrosine kinase inhibitor for the treatment of metastatic RET-driven non-small cell lung cancer. Tirbanibulin A tyrosine kinase and tubulin inhibitor used to treat actinic keratosis on the face or scalp. Trilaciclib A CDK4 and CDK6 inhibitor to reduce the risk of chemotherapy induced myelosuppression. Fosdenopterin An exogenous form of cyclic pyranopterin monophosphate (cPMP) used as a replacement substrate in patients with molybdenum cofactor deficiency (MoCD) type A. Amisulpride A dopamine D2 receptor antagonist used in the treatment of acute and chronic schizophrenia, and in the prevention and treatment of postoperative nausea and vomiting in adults. Infigratinib An FGFR inhibitor used to treat locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) rearrangement. Avapritinib A selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors. Belzutifan An inhibitor of hypoxia-inducible factor 2α used as an antineoplastic in the treatment of certain cancers associated with von Hippel-Lindau (VHL) disease. Fexinidazole An orally bioavailable 2-substituted 5-nitroimidazole used to treat early- and late-stage human African trypanosomiasis caused by Trypanosoma brucei gambiense. Tepotinib An oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations. Niraparib A poly-ADP ribose polymerase inhibitor used to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer responding to platinum based chemotherapy. Olutasidenib An isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test. Brexpiprazole A serotonin–dopamine activity modulator used in the treatment of major depressive disorder as an adjunct, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease. Capivasertib A serine/threonine kinase inhibitor used to treat hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer Repotrectinib A tyrosine kinase inhibitor used to treat locally active or metastatic non-small cell lung cancer Deuruxolitinib A Janus Kinase inhibitor used to treat severe alopecia areata in adults. - Drugs & Drug Targets